Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

SYSMEX-EUROPA

Sysmex Europe designs and produces laboratory and hematology diagnostic solutions, including instruments, reagents, c... read more Featured Products: More products

Download Mobile App




Automated Immunoassay Systems Evaluated for KL‐6 Antigen Quantification

By LabMedica International staff writers
Posted on 20 Nov 2019
Interstitial lung disease (ILD) is a group of diseases characterized by various forms of pulmonary interstitial inflammation and fibrosis, which are usually chronic, progressive, and fatal, causing death 2‐5 years after diagnosis in most patients.

The sputum saccharide chain antigen, Krebs von den Lungen‐6 (KL‐6), is a serum biomarker of lung injury. More...
Since the most important feature of ILD is repeated damage or repair of type II alveolar epithelial cells, KL‐6 is secreted by these cells, and therefore KL‐6 is considered the most accurate biomarker in the diagnosis of ILD.

Immunologists at The First Affiliated Hospital of Guangzhou Medical University (Guangzhou, China) and their associates collected serum samples from 145 individuals between May 2018 and October 2018. Of 145 subjects, 25 had lung cancer, 56 had ILD, 35 had other respiratory diseases, and 29 were healthy individuals (control group) who underwent regular health checkup. There were 83 (57.24%) men and 62 women with a median age distribution of 56 years (interquartile range: 46-67).

The scientists evaluated the basic performance of KL‐6 assays using the HISCL‐5000 analyzer (Sysmex Corporation, Kobe, Japan), a fully automated immunochemistry analyzer that employs a chemiluminescence enzyme immunoassay (CLEIA) methodology with a two‐step sandwich immunoassay. The results were compared with those from the LUMIPULSE G1200 analyzer (Fujirebio Europe N.V., Zwijnaarde, Belgium). The analytical measurement ranges of HISCL‐5000 and LUMIPULSE G1200 were 10‐6,000 U/mL and 50‐10,000 U/mL, respectively.

The scientists reported that with a cutoff level of 500 U/mL, comparing the two systems, the agreement, sensitivity, specificity, and kappa value were 99.2%, 100%, 98.63%, and 0.984, respectively. Spearman's correlation and intraclass correlation coefficient (ICC) showed that there was a strong correlation between serum KL‐6 levels measured by the two systems. The clinical diagnosis agreement rate in both systems was >80%. The KL‐6 level in the ILD group was significantly higher than that in the non‐ILD groups, and the KL‐6 level (1,558, 726‐2,772.5) in the ILD group detected by HISCL‐5000 was significantly higher than that in the lung cancer group (339, 207‐424), other respiratory disease group (249, 194‐366), and control group (198, 131.5‐297).

The authors concluded that the HISCL‐5000 CLEIA system has a high diagnostic efficiency. The method can be applied to the quantitative detection of serum KL‐6 in patients with respiratory diseases. Compared with those in other respiratory diseases, the serum KL‐6 level in patients with ILD is significantly increased, suggesting that clinicians can use KL‐6 in the auxiliary diagnosis of ILD. The study was published on November 6, 2019 in the Journal of Clinical Laboratory Analysis.

Related Links:
The First Affiliated Hospital of Guangzhou Medical University
Sysmex Corporation
Fujirebio Europe N.V.



New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Rapid Test Reader
DIA5000
New
Silver Member
Quality Control Material
Multichem ID-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.